Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Research & Development (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Research & Development for 14 consecutive years, with $20.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 24.58% year-over-year to $20.9 million, compared with a TTM value of $99.9 million through Dec 2025, down 18.59%, and an annual FY2025 reading of $106.7 million, down 18.81% over the prior year.
  • Research & Development was $20.9 million for Q4 2025 at Enanta Pharmaceuticals, down from $23.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $48.9 million in Q3 2021 and bottomed at $20.9 million in Q4 2025.
  • Average Research & Development over 5 years is $36.2 million, with a median of $36.3 million recorded in 2023.
  • The sharpest move saw Research & Development soared 35.5% in 2021, then plummeted 33.14% in 2024.
  • Year by year, Research & Development stood at $48.5 million in 2021, then fell by 15.75% to $40.9 million in 2022, then fell by 11.08% to $36.4 million in 2023, then dropped by 23.96% to $27.7 million in 2024, then decreased by 24.58% to $20.9 million in 2025.
  • Business Quant data shows Research & Development for ENTA at $20.9 million in Q4 2025, $23.8 million in Q3 2025, and $27.2 million in Q2 2025.